Background: Tuberculosis is a multifactorial disease, with the evolution and response to treatment being determined by the interaction between the genotype of M. tuberculosis and the human genotype. Immunological adaptogenic treatment is an important pathogenetical treatment of tuberculosis. BioR medicine obtained from the biomass of Spirulina platensis exhibits an antioxidant activity and immunomodulator activity. Extract of Eleuterococc increases the body’s resistance, diminishing the level of the body stress syndrome. The aim of the research was the comparative analysis of adaptive reactivity and immune resistance in the patients with pulmonary tuberculosis treated with immunomodulator drug BioR versus extract of Eleuterococ. Material and methods: adaptive reactivity and immune resistance indices were analyzed in a total number of 113 patients hospitalized in clinical subdivisions of Chiril Draganiuc Institute of Pneumophthysiology. Results: Both drugs showed a high adaptogenic capacity, a high efficiency on the level of immune reactivity, although it was appreciated that the immune modulator drug BioR is more efficient than Eleuterococ extract associated medicine to antituberculois treatment of patients with pulmonary tuberculosis. Conclusions: The combination of adaptogenic drugs: extract of Eleuterococ and BioR with anti-TB treatment enhances its efficacy, demonstrated by normalizing of the adaptogenic reactions, also enhancing the immune and preimmune resistance indices. Both drugs can be recommended for inclusion as immune modulators in the standard anti-TB treatment with the aim to ensure high therapeutical effectiveness.